MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$80,658
Free Cash flow
-$7,121,674
Unit: Dollar
Positive Cash Flow Breakdown
Maturities/(purchase) of short-t...
Change in estimate for legal con...
Prepaid expenses
Others
Negative Cash Flow Breakdown
Net loss
Other current liabilities
Other current assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-10,786,594
-12,509,361
-14,441,963
-12,754,660
Write-down of vendor deposits
-
-
0
0
Depreciation and amortization
157,598
172,886
180,009
178,898
Stock-based compensation expense
1,271,210
1,496,989
1,618,540
1,914,136
Amortization of debt discount
-
-
0
0
Change in estimate for legal contingencies
-
-
0
-
Gains from asset sales
178,200
-
179,987
91,400
Loss from disposal of assets
-589,660
-7,615
0
0
Change in estimate for legal contingency
3,250,000
-
-
0
Prepaid expenses
-808,370
396,781
-3,207,421
2,448,499
Right-of-use assets
1
170,367
-
-
Other current assets
244,777
-617,231
-48,139
166,752
Other assets
-27,600
-18,001
0
0
Accounts payable
341,471
1,903,517
-791,574
-397,505
Accrued interest related party-Related Party
-
-
0
0
Accrued interest related party-Nonrelated Party
-
-
0
0
Accrued payroll liabilities
456,174
-1,035,082
348,700
52,750
Operating lease liability
-25,284
-212,666
-48,199
-45,695
Other current liabilities
-2,788,903
1,209,367
292,427
394,352
Net cash used in operating activities
-7,121,674
-8,557,917
-9,766,487
-13,364,375
Proceeds from the sale of assets, net of sales costs
178,200
-
179,987
91,400
Purchase of short-term investment
-
-
2,983,494
-7,875,810
Maturities/(purchase) of short-term investments, net of maturities
-6,963,830
-10,895,109
-
-
Purchase of property and equipment
0
0
0
0
Cash from asset disposition
0
850
-
-
Net cash provided by (used in) investing activities
7,142,030
10,895,959
-2,803,507
7,967,210
Proceeds from warrant exercises
-
-
0
-
Purchase under employee stock purchase plan
6,274
-
11,413
18,158
Proceeds from the issuance of common stock and warrants, net of equity issuance costs of 0 and 6,434,447, respectively
-
-
-
0
Proceeds from option exercises
-
-
0
-
Repayment of insurance premium loan payable
107,288
71,525
-
-
Net cash (used in) provided by in financing activities
-101,014
-71,525
11,413
0
Net increase (decrease) in cash and cash equivalents
-80,658
2,266,517
-12,558,581
-5,397,165
Cash and cash equivalents, beginning of period
8,149,015
5,882,498
18,441,079
68,415,741
Cash and cash equivalents, end of period
8,068,357
8,149,015
5,882,498
18,441,079
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities/(purchase) of short-term
investments, net of...
-$6,963,830
Proceeds from the sale of
assets, net of sales...
$178,200
(99.41%↑ Y/Y)
Net cash provided by
(used in) investing...
$7,142,030
(128.96%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$80,658
(99.82%↑ Y/Y)
Canceled cashflow
$7,142,030
Change in estimate for
legal contingency
$3,250,000
Stock-based compensation
expense
$1,271,210
(-69.98%↓ Y/Y)
Prepaid expenses
-$808,370
(-176.13%↓ Y/Y)
Loss from disposal of
assets
-$589,660
Accrued payroll
liabilities
$456,174
(285.26%↑ Y/Y)
Accounts payable
$341,471
(-86.79%↓ Y/Y)
Depreciation and
amortization
$157,598
(-56.76%↓ Y/Y)
Other assets
-$27,600
Right-of-use assets
$1
Purchase under employee
stock purchase plan
$6,274
(-65.45%↓ Y/Y)
Net cash used in
operating activities
-$7,121,674
(64.27%↑ Y/Y)
Canceled cashflow
$6,902,084
Net cash (used in)
provided by in financing...
-$101,014
(-656.31%↓ Y/Y)
Canceled cashflow
$6,274
Net loss
-$10,786,594
(62.45%↑ Y/Y)
Other current
liabilities
-$2,788,903
(-271.95%↓ Y/Y)
Other current assets
$244,777
(116.58%↑ Y/Y)
Gains from asset sales
$178,200
(99.41%↑ Y/Y)
Operating lease liability
-$25,284
(71.28%↑ Y/Y)
Repayment of insurance
premium loan payable
$107,288
Buy us a coffee
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)